公开(公告)号：US20240325536A1

公开(公告)日：2024-10-03

申请号：US18281532

申请日：2022-03-29

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Tobias Deuse

IPC分类号： A61K39/00 ,  A61K35/36 ,  A61K35/39 ,  C07K14/725 ,  C07K14/735 ,  C07K16/28

CPC分类号： A61K39/464412 ,  A61K35/36 ,  A61K35/39 ,  A61K39/4611 ,  A61K39/4621 ,  A61K39/4631 ,  C07K14/7051 ,  C07K14/70535 ,  C07K16/2803 ,  A61K2239/26 ,  C07K2317/622

摘要： The invention provides, for the first time, cells that express truncated or modified Fc Receptor proteins (e.g. CD16t, CD32t, or CD64t) to evade antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). The cells may be pluripotent cells, including hypoimmune pluripotent cells (HIP) or ABO blood type O Rhesus Factor negative HIP cells (HIPO−), that express a truncated or modified Fc Receptor. The invention encompasses cells derived from the pluripotent cells as well as primary cells. The cells may also be differentiated cells, including chimeric antigen receptor (CAR) cells, T cells, natural killer (NK) cells, endothelial cells, dopaminergic neurons, neuroglial cells, pancreatic islet cells, pancreatic beta cells, thyroid cells, fibroblasts, hepatocytes, cardiomyocytes, or retinal pigment endothelium cells.

公开(公告)号：US20240309389A1

公开(公告)日：2024-09-19

申请号：US18279709

申请日：2022-02-24

申请人： TEIKYO HEISEI UNIVERSITY

发明人： Ryosuke Nakamura ,  Haruyo Akiyama ,  Satoshi Tadokoro ,  Kenichi Kumasaka

IPC分类号： C12N15/62 ,  C07K14/735 ,  C12N15/63 ,  C12Q1/02

CPC分类号： C12N15/62 ,  C07K14/70535 ,  C12N15/63 ,  C12Q1/02 ,  C07K2319/03

摘要： Provided herein is a chimeric FcεRI α-chain gene including a first base sequence encoding an extracellular domain of a human FcεRI α-chain and a second base sequence encoding at least a transmembrane domain of a non-human animal FcεRI α-chain. Also provided herein is a chimeric FcεRI α-chain protein that is an expression product of the chimeric FcεRI α-chain gene, and a non-human animal cell including the chimeric FcεRI α-chain gene. Also provided herein is an analysis kit including the cells and an analysis method using the cells.

公开(公告)号：US12025620B2

公开(公告)日：2024-07-02

申请号：US16981947

申请日：2019-03-14

申请人： SVAR LIFE SCIENCE AB

发明人： Michael Tovey ,  Christophe Lallemand

IPC分类号： G01N33/68 ,  C07K14/705 ,  C07K14/735 ,  C07K16/24 ,  C07K16/28

CPC分类号： G01N33/6854 ,  C07K14/70532 ,  C07K14/70535 ,  C07K16/241 ,  C07K16/2863 ,  C07K2317/732

摘要： The present invention relates novel cells and their use in methods for determining the antibody-dependent cell-mediated cytotoxicity (ADCC) or antibody-dependent cell-mediated phagocytosis (ADCP) in a sample.

公开(公告)号：US20240092865A1

公开(公告)日：2024-03-21

申请号：US18476132

申请日：2023-09-27

申请人： Yunbiao LU

发明人： Yunbiao LU

IPC分类号： C07K14/705 ,  A61K35/17 ,  A61K47/68 ,  A61P37/06 ,  C07K14/735

CPC分类号： C07K14/70596 ,  A61K35/17 ,  A61K47/6811 ,  A61P37/06 ,  C07K14/70532 ,  C07K14/70535 ,  A61K38/00 ,  C07K2319/30

摘要： An active form (BY-001) of a homomultimeric chimeric protein PD-L1/Fc-gamma1 may have a composition of 25% dimer, 30% tetramer and 45% hexamer. BY-001 consists of two distinct functional domains at the aggregated state, one is the extracellular domain of PD-L1 and another one is the IgG1 Fc region. Accordingly, the first functional domain of PD-L1 at its aggregated state is more effective in suppressing the activity of CD3+ and CD28+ T cells; while, on the other hand, the second functional domain of FC-gamma1 at its aggregated state exerts only the suppressive effects on the immune cell bearing the Fc-gamma receptors. Thus, the features provided in present invention indicate that BY-001 regulates the functions of immune cells subsets that are responsible for the peripheral immune tolerance, which makes BY-001 potential to help restore or maintain the peripheral immune tolerance in patients with autoimmune diseases or in recipients of allografts.

公开(公告)号：US20240083976A1

公开(公告)日：2024-03-14

申请号：US18363747

申请日：2023-08-02

申请人： SOUTH CHINA UNIVERSITY OF TECHNOLOGY

发明人： Jun WANG ,  Yanan FAN ,  Song SHEN ,  Qianni YE

IPC分类号： C07K14/76 ,  A61K47/64 ,  A61K47/68 ,  A61K47/69 ,  C07K14/735 ,  C07K19/00

CPC分类号： C07K14/76 ,  A61K47/643 ,  A61K47/6849 ,  A61K47/6937 ,  C07K14/70535 ,  C07K19/00 ,  C07K2319/31

摘要： Provided is a fusion protein, comprising a protein having a hydrophobic region, a peptide linker, a protein fusion receptor. The peptide linker links the protein having a hydrophobic region to the protein fusion receptor. The protein fusion receptor is an Fc receptor fragment that specifically recognizes an Fc fragment of an antibody, and the protein having a hydrophobic region is a serum albumin. Also provided is a nano-assembly consisting of the fusion protein and a hydrophobic degradable polyester and a derivative thereof. Also provided is an application of the nano-assembly having excellent stability in an antibody delivery platform. The constructed nano-assembly platform is creatively applied in the preparation of immunotherapeutic drugs or therapeutic drugs for tumors or autoimmune diseases or inflammations.

公开(公告)号：US20240083939A1

公开(公告)日：2024-03-14

申请号：US18505180

申请日：2023-11-09

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Tomoyuki Igawa ,  Zenjiro Sampei ,  Tetsuya Wakabayashi ,  Eriko Ito

IPC分类号： C07K1/22 ,  C07K14/735 ,  C07K16/28 ,  C07K16/30 ,  C07K16/36 ,  C07K16/46

CPC分类号： C07K1/22 ,  C07K14/70535 ,  C07K16/2809 ,  C07K16/2866 ,  C07K16/303 ,  C07K16/36 ,  C07K16/468 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/66 ,  C07K2317/94 ,  C07K2319/30

摘要： The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.

公开(公告)号：US20240075141A1

公开(公告)日：2024-03-07

申请号：US18186133

申请日：2023-03-17

申请人： Wugen, Inc.

发明人： You ZHOU ,  Matthew COOPER ,  Elizabeth SCHRAMM

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K14/735 ,  C07K16/10 ,  C07K16/28

CPC分类号： A61K39/4631 ,  A61K39/4613 ,  A61P35/00 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/70507 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70535 ,  C07K14/70596 ,  C07K14/7155 ,  C07K16/1063 ,  C07K16/2803 ,  C07K16/2806 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2851 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2896 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30

摘要： Among the various aspects of the present disclosure is the provision of improved chimeric receptor constructs for NK cells, NK cells containing such receptors and methods of making and using same.

公开(公告)号：US20240018258A1

公开(公告)日：2024-01-18

申请号：US18458692

申请日：2023-08-30

申请人： Pfizer Inc.

发明人： Gloria Hoi Ying LIN ,  Natasja Nielsen VILLER ,  Mark Michael WONG ,  Jeffrey Todd WINSTON ,  Robert Adam UGER

IPC分类号： C07K16/28 ,  A61P35/00 ,  C07K14/735

CPC分类号： C07K16/2896 ,  A61P35/00 ,  C07K14/70535

摘要： CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRPαFc is enhanced in the presence of daratumumab. Specific combinations include SIRPαFc forms that comprise an Fc that is either IgG1 or IgG4 isotype. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.

公开(公告)号：US20230372545A1

公开(公告)日：2023-11-23

申请号：US18050216

申请日：2022-10-27

申请人： Fox Chase Cancer Center

发明人： Kerry S. Campbell

IPC分类号： A61K49/00 ,  C07K14/735 ,  A61K39/395 ,  A61K35/17 ,  C07K16/28 ,  C12N5/0783 ,  C07K16/32 ,  G01N33/50 ,  A61K35/12

CPC分类号： A61K49/00 ,  C07K14/70535 ,  A61K39/39533 ,  A61K39/39558 ,  A61K35/17 ,  C07K16/283 ,  C12N5/0646 ,  C07K16/32 ,  C07K16/28 ,  G01N33/5011 ,  G01N33/5047 ,  A61K2035/124 ,  C07K2317/31 ,  C07K2317/24 ,  C12N2510/00 ,  C12N2501/23 ,  C12N2503/02 ,  C12N2503/00 ,  C07K2317/732

摘要： The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ,TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

公开(公告)号：US20230348880A1

公开(公告)日：2023-11-02

申请号：US17802499

申请日：2021-02-27

申请人： Huahui Health Ltd. ,  NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING

发明人： Wenhui Li ,  Yonghe Qi ,  Jianhe Chen ,  Jianhua Sui ,  Juan Liu ,  Fengfeng Mao ,  Ximing Liu

IPC分类号： C12N9/48 ,  A61P37/02 ,  C12N15/63 ,  C07K14/735

CPC分类号： C12N9/485 ,  C12Y304/17023 ,  A61P37/02 ,  C12N15/63 ,  C07K14/70535 ,  C07K2319/30

摘要： A soluble ACF and a truncated form thereof, a fusion protein thereof and preparation methods therefor. A soluble ACEI and a truncated form thereof, as well as a use of the fusion protein in the preparation of a drug for an ACEI-related disease.